There’s no denying the best sector for investors right now is the COVID-19 vaccine plays We at Insider Financial have nailed quite a few this year, from Inovio Pharmaceuticals to Moderna and most recently with Vaxart. Now we are turning our attention to Heat Biologics stock, another Covid-19 vaccine player that has yet to make a huge move like Inovio, Moderna, and Vaxart.
While the entire world was talking yesterday about Moderna’s vaccine, Heat Biologics stock put out a tweet that really caught our attention.
Congratulations to @moderna_tx on encouraging Phase 1 results for their #COVID19 vaccine. Our T-cell activating vaccine may be highly synergistic with their antibody-generating vaccine to provide an extra layer of T-cell protection for high-risk patients that need it most.
— Heat Biologics (@HeatBiologics) July 15, 2020
For those of you that don’t know, synergistic means causing or involving synergy. The power of working together is greater than the power achieved by working separately, i.e. the synergistic effect of two drugs given at the same time.
If this is true, this is blockbuster news. Heat Biologics stock has a market cap of just $114 million compared to Moderna’s $32 billion. Heat Biologics is the SS Minnow and Moderna is Moby Dick.
About Heat Biologics Stock
First up, here’s a little background info for those of you that aren’t familiar with Heat Biologics stock. Heat Biologics is a biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system.
The company’s gp96 platform is designed to activate immune responses against cancer or pathogenic antigens. Multiple product candidates in development leveraging the gp96 platform, including HS-110 which has completed enrollment in its Phase 2 trial, HS-130 in Phase 1, and a COVID-19 vaccine program in preclinical development.
In addition, Heat is also developing a pipeline of proprietary immunomodulatory antibodies, including PTX-35 which is enrolling in a Phase 1 trial. For more information, please visit www.heatbio.com.
Last month, the first patient was treated in Heat Biologics’ first-in-human Phase 1 clinical trial evaluating PTX-35, the first antibody product candidate.
This study is expected to enroll up to 30 patients with advanced solid tumors refractory to standard of care.
The objectives of the study include safety evaluation, determination of the recommended Phase 2 dose as well as exploratory analyses of clinical benefit, and immunological effect of PTX-35.
This trial is supported by a $15.2M grant from the Cancer Prevention and Research Institute of Texas.
Covid-19 Vaccine Program
Heat Biologics has achieved stable co-expression of gp96/nCoV-S protein, as measured by both immunofluorescence and ELISA, in its clinically validated human cell line, enabling selection of the COVID-19 vaccine. These steps are necessary precursors to completion of the company’s vaccine in preparation for its manufacture and use in clinical trials.
Heat Biologics is on track to complete the design and development of the COVID-19 vaccine in July and expects its gp96/nCoV-2 expressing cell line to be available for clinical-grade manufacturing with a partner, Waisman Biomanufacturing, in early August.
Moderna’s Vaccine Program
Right now all the talk is around Moderna. However, there are problems with Moderna. Moderna has no FDA approved drugs and there are a number of questions about its vaccine. Moderna does not have a lock on being the only Covid-19 vaccine.
Just take a look at one of the 45 volunteers in Moderna Therapeutics’ coronavirus vaccine trial. Ian Haydon, 29, shared his experience after receiving a coronavirus jab which followed a visit to the urgent care unit, vomiting then passing out, and eventually recovering after a few days. He is one of the four people reported to have experienced severe adverse reactions to the candidate vaccine.
Closely followed investor known as andybiotech on twitter highlighted that Moderna’s publication provided ” 1) No data for the most vulnerable older (>55) population 2) Second dose absolutely necessary 3) Safety profile less than desirable 4) Durability of neutralizing Ab not so encouraging (decline from day 43~57) 5) Very low CD8 T-cell responses”, which adds a bit of caution to the news.
While the tweet from Heat Biologics stock does excite the bulls, we need a press release to confirm the synergistic news. If the data is indeed synergistic, Moderna will be cutting a check to buy Heat Biologics before the ink is dry on the PR. If that happens, buckle up and prepare for blast off as the dollars are stake for Moderna is in the tens of billions. Heat Biologics could write its own check then.
As always, good luck to all (except the shorts)!
We will be updating our subscribers as soon as we know more. For the latest updates on NASDAQ:HTBX, sign up today!
Disclosure: We have no position in NASDAQ:HTBX or any of the securities mentioned. We wrote this article ourselves and it expresses our own opinions. We are not receiving compensation for it. We have no business relationship with any company whose stock is mentioned in this article.